



Contents – click on physician name to link to his/her publications

Anne Greist, MD..... 2

Publications 2

Presentations 2

Sweta Gupta, MD 2

Publications 2

Presentations 3

Brandon Hardesty, MD 4

Presentations 4

Jennifer Maahs, PNP 4

Publications 4

Presentations 4

Charles Nakar, MD 6

Publications 6

Presentations 6

Angeli Rampersad, MD 7

Publications 7

Presentations 7

Amy Shapiro, MD 8

Publications 8

Presentations 13

Anand Tandra, MD 13

Publications 13

Other IHTC Staff 14

Publications 14

Presentations 15

Anne Greist, MD

Publications

Amin C, Sharathkumar A, **Greist A**. Chapter 70 - Bleeding diathesis and hemophilias. In: José B, José MF, eds. Handbook of Clinical Neurology: Elsevier; 2014:1045-59.

Greist A, Shapiro A, Kruse-Jarres R, St. Louis J, Smith H, Gomperts E. Abstract FP-MO-01.1-1: Efficacy and safety of B-domain deleted recombinant porcine factor FVIII (OB-1) in the treatment of acquired hemophilia A: interim results. Haemophilia 2012;18(Suppl 3):1.

Louis JS, Kruse-Jarres R, **Greist A**, Shapiro AD, Smith H, Drebes AB, Lozier JN, Gomperts ED. Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results. ASH Annual Meeting Abstracts 2012;120(21):2224.

Nakar C, Haddix C, Meschino N, Sagar J, Menshouse E, Fuentes I, **Greist A**, Shapiro A. Abstract P-MO-543: Development and use of a surgical database to standardize care, assess efficacy and outcomes in bleeding disorders patients: report of 1184 procedures from a single center. Journal of Thrombosis and Haemostasis 2011;9(Suppl 2).

Sharathkumar A, Soucie JM, Trawinski B, **Greist A**, Shapiro AD. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia 2011;17(4):597-604.

Presentations

Asirwa FC, **Greist A**, Roberson C. AMPATH Hematology: Collaboration between Indiana Hemophilia & Thrombosis Center (IHTC), Indiana University and Moi University, Eldoret (Kenya). Poster presentation at the 2nd Global Sickle Cell Disease Network, March 2012, Atlanta, GA.

Nakar C, Haddix C, Meschino N, Sagar J, Menshouse E, Fuentes I, **Greist A**, Shapiro A. Development and use of a surgical database to standardize care, assess efficacy and outcomes in bleeding disorder patients: report of 1184 procedures from a single center. Poster presentation at XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH) 57th Annual SSC Meeting, July 2011, Kyoto, Japan.

Sweta Gupta, MD

Publications

James AH, Konkle BA, Kouides P, Ragni MV, Thames B, **Gupta S**, Sood S, Fletcher SK, Philipp CS. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia 2015;21(1):81-7.

Heiman M, **Gupta S**, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. Haemophilia 2014;20(3):407-12.

Plasminogen activator inhibitor type 1 deficiency. 2014. (Accessed July 30, 2014, at www.rarecoagulationdisorders.org.)

Malec LM, Moore CG, Bennett CM, Yee DL, Kerlin BA, Witmer C, Gunawardena S, Kulkarni R, **Gupta S**, Kouides PA, Brown D, Bujnicki HL, Ragni MV. Validation study of the composite score to identify von Willebrand disease in children. 2013;122(21):2356.

Gupta S, Shapiro A. New recombinant factor concentrates. International Monitor on Hemophilia 2013;21:3-8.

Gupta S, Siddiqi A-E-A, Soucie JM, Manco-Johnson M, Kulkarni R, Lane H, Ingram-Rich R, Gill JC, of the Joint Outcomes Committee of Universal Data Collection and the Hemophilia Treatment Centres Network. The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia. British Journal of Haematology 2013;161:424-33.

Nakar C, **Gupta S**, Xavier F, Rampersad A, Natarajan K. Abstract PO 301: A case of extensive recalcitrant IVC thrombosis in a teenager with Behcet disease. Journal of Thrombosis & Haemostasis 2013;11(Suppl 2):1132-33.

Xavier F, Maahs J, Hallet R, Nakar C, Rampersad A, **Gupta S**, Shapiro A. Abstract PO 173: Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. Journal of Thrombosis & Haemostasis 2013;11(Suppl 2):1086.

Malec LM, Moore CG, Bennett CM, Yee DL, Kerlin BA, Witmer C, Gunawardena S, Kulkarni R, **Gupta S**, Kouides PA, Brown D, Bujnicki HL, Ragni MV. Validation Study Of The Composite Score To Identify Von Willebrand Disease in Children. Blood 2013;122(21):2356.

Gupta S, Siddiqi A, Soucie JM, Manco-Johnson M, Kulkarni R, Lane H, Ingram-Rich R, Gill J. Abstract B9: Effect of secondary prophylaxis versus episodic treatment on range of motion of a target joint in hemophilia patients. American Journal of Hematology 2012;87(Suppl 1).

Presentations

Nakar C., **Gupta S.**, Xavier F., Rampersad A., Hallett R., Natarajan K. A Case of Extensive Recalcitrant IVC Thrombosis in a Teenager with Behçet Disease. Poster presentation at XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29-July 4 2013, Amsterdam, Netherlands.

Xavier F, Maahs J, Hallett R, Nakar C, Rampersad A, **Gupta S**, Shapiro A. Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. Poster presentation at XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29- July 4 2013, Amsterdam, Netherlands.

Gupta S. Update on the Diagnosis and Treatment of Von Willebrand Disease. Oral presentation at Indiana Academy of Family Physicians. October 2012.

Gupta S. Comparison of quality of life in an Amish and Non Amish cohort affected with Von Willebrand disease. Poster presentation at Scientific and Standardization Committee (SSC) Annual Meeting, June 2012, Liverpool, UK.

Gupta S. Effect of Secondary Prophylaxis versus Episodic Treatment on Range of Motion of a Target Joint in Hemophilia Patients. Poster presentation at Thrombosis and Hemostasis Summit of North America (THSNA), May 2012, Chicago, IL.

Brandon Hardesty, MD

Presentations

Hardesty B. Immunophenotype of Pre-Engraftment Cells after Minimal Intensity Allotransplantation. Poster presentation at Federation of Clinical Immunology Societies Annual Meeting 2012. July 2012, Vancouver, Canada.

Hardesty B. Lineage-specific Chimerism Analysis of Post-infusion, Pre-engraftment Sorted Peripheral Blood Cells after Minimal Intensity Allotransplantation. Poster presentation at Federation of Clinical Immunology Societies Annual Meeting 2012. July 2012, Vancouver, Canada.

Jennifer Maahs, PNP

Publications

Nakar C, Manco-Johnson MJ, Lail A, Donfield SM, **Maahs J**, Chong Y, Blades TA, Shapiro AD. Abstract: Prompt immune tolerance induction at inhibitor diagnosis regardless of titer may increase overall success in hemophilia A with inhibitors: experience of two US centers. 2013;122(21):575.

Rampersad AG, Shapiro AD, Rodriguez-Merchan EC, **Maahs JA**, Akins S, Jimenez-Yuste V. Radiosynovectomy: review of the literature and report from two haemophilia treatment centers. Blood Coagul Fibrinolysis 2013;24(5):465-70.

Xavier F, **Maahs J**, Hallet R, Nakar C, Rampersad A, Gupta S, Shapiro A. Abstract PO 173: Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. Journal of Thrombosis & Haemostasis 2013;11(Suppl 2):1086.

Escobar M, **Maahs J**, Hellman E, Donkin J, Forsyth A, Hroma N, Young G, Valentino LA, Tachdjian R, Cooper DL, Shapiro AD. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres. Haemophilia 2012;18(6):971-81.

Byams VR, Kouides PA, Kulkarni R, Baker JR, Brown DL, Gill JC, Grant AM, James AH, Konkle BA, **Maahs J**, Dumas MM, McAlister S, Nance D, Nugent D, Philipp CS, Soucie JM, Stang E. Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia 2011;17(Suppl 1):6-13.

Presentations

Maahs J. Hemophilia Pharmacy Management: Steps for Success With Managed Care and Specialty Pharmacy. Oral presentation at National Hemophilia Foundation (NHF) 66th Annual Meeting. September 2014, Washington, D.C.

Maahs J. Overcoming Odds. Oral presentation at National Hemophilia Foundation (NHF) 66th Annual Meeting. September 2014, Washington, D.C.

Maahs J. Nursing Case Studies. Oral presentation at National Hemophilia Foundation (NHF) 66th Annual Meeting. September 2014, Washington, D.C.

Maahs J. Eloctate: A new option for the Management of Hemophilia A. [Oral presentation](#) at International Society of Thrombosis and Hemostasis (ISTH). June 2014, Milwaukee, WI.

Nakar C, Manco-Johnson MJ, Lail A, Donfield S, **Maahs J**, Chong Y, Blades T, Shapiro A. Prompt Immune Tolerance Induction at Inhibitor Diagnosis Regardless of Titer May Increase Overall Success in Hemophilia A with Inhibitors: Experience of Two US Centers. [Oral presentation](#) at American Society of Hematology (ASH) 56th Annual Meeting. December 2013, New Orleans, LA.

Maahs J. Hemophilia and Managed Care. [Oral presentation](#) at National Hemophilia Foundation (NHF) 65th Annual Meeting. October 2013, Anaheim, CA.

Maahs J. Genetics and Hemophilia. [Oral presentation](#) at National Hemophilia Foundation (NHF) 65th Annual Meeting. October 2013, Anaheim, CA.

Maahs J. Understanding VWD. [Oral presentation](#) at National Hemophilia Foundation (NHF) 65th Annual Meeting. October 2013, Anaheim, CA.

Xavier F, **Maahs J**, Hallett R., Nakar C., Rampersad A., Gupta S., Shapiro A. Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. [Poster presentation](#) at XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29-July 4 2013, Amsterdam, The Netherlands.

Maahs J. Developing Care in Developing Countries. [Oral presentation](#) at International Society of Thrombosis and Hemostasis (ISTH). June 29-July 4, 2013; Amsterdam, Holland, The Netherlands.

Maahs J. Tattoos, Gages and Piercings. [Oral presentation](#) at National Hemophilia Foundation (NHF) 64th Annual Meeting. November 2012, Orlando, FL.

Maahs J. Telemedicine. [Oral presentation](#) at National Hemophilia Foundation (NHF) 64th Annual Meeting. November 2012, Orlando, FL.

Maahs J. Management of Patients with VWD. [Oral presentation](#) at National Hemophilia Foundation (NHF) 64th Annual Meeting. November 2012, Orlando, FL.

Maahs J. Resources for Rare Bleeding Disorders. [Oral presentation](#) at World Federation of Hemophilia (WFH) World Congress. July 2012, Paris, France.

Maahs J. Surgical Management of Persons with Hemophilia. [Oral presentation](#) at National Hemophilia Foundation (NHF) 63rd Annual Meeting. November 2011, Chicago, IL.

Maahs J. Platelet Disorders. [Oral presentation](#) at National Hemophilia Foundation (NHF) 63rd Annual Meeting. November 2011, Chicago, IL.

Maahs J. Birth, Action, Bleeds, Empowerment. [Oral presentation](#) at National Hemophilia Foundation (NHF) 63rd Annual Meeting. November 2011, Chicago, IL.

Maahs J. Hemophilia and Aging. [Oral presentation](#) at International Society of Thrombosis and Hemostasis (ISTH). July 2011, Kyoto, Japan.

Charles Nakar, MD

Publications

Nakar C, Manco-Johnson MJ, Lail A, Donfield SM, Maahs J, Chong Y, Blades TA, Shapiro AD. Abstract: Prompt immune tolerance induction at inhibitor diagnosis regardless of titer may increase overall success in hemophilia A with inhibitors: experience of two US centers. 2013;122(21):575.

Nakar C, Shapiro A. The optimal time to initiate immune tolerance induction. The International Monitor 2013;21(1):21-2.

Nakar C, Xavier F. Abstract PO 302: Splenic infarction in a teenager associated with oral contraceptives, elevated lipoprotein a, and median arcuate ligament syndrome. Journal of Thrombosis & Haemostasis 2013;11(Suppl 2):1133.

Tuval-Kochen L, Paglin S, Keshet G, Lerenthal Y, **Nakar C**, Golani T, Toren A, Yahalom J, Pfeffer R, Lawrence Y. Eukaryotic initiation factor 2alpha--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment. PLoS One 2013;8(10):e77260.

Xavier F, Maahs J, Hallet R, **Nakar C**, Rampersad A, Gupta S, Shapiro A. Abstract PO 173: Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. Journal of Thrombosis & Haemostasis 2013;11(Suppl 2):1086.

Nakar C, Shapiro A. Inhibitors, tolerance and alchemy. The International Monitor 2012;20(1):33-4.

Hemophilia: neurologic aspects. 2012. (Accessed August 1, 2014, at <http://www.medlink.com>.)

Nakar C, Haddix C, Meschino N, Sagar J, Menshouse E, Fuentes I, Greist A, Shapiro A. Abstract P-MO-543: Development and use of a surgical database to standardize care, assess efficacy and outcomes in bleeding disorders patients: report of 1184 procedures from a single center. Journal of Thrombosis and Haemostasis 2011;9(Suppl 2).

Nakar C, Gupta S, Xavier F, Rampersad A, Natarajan K. Abstract PO 301: A case of extensive recalcitrant IVC thrombosis in a teenager with Behcet disease. Journal of Thrombosis & Haemostasis 2013;11(Suppl 2):1132-33.

Presentations

Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, Chong Y, Blades T, Shapiro A. Prompt Immune Tolerance Induction at Inhibitor Diagnosis Regardless of Titer May Increase Overall Success in Hemophilia A with Inhibitors: Experience of Two US Centers. Oral presentation at American Society of Hematology (ASH) 56th Annual Meeting. December 2013, New Orleans, LA.

Xavier F, Maahs J., Hallett R., **Nakar C.**, Rampersad A., Gupta S., Shapiro A. Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. Poster presentation at XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29- July 4 2013, Amsterdam, The Netherlands.

Nakar C., Hallett R., Xavier F. Splenic infarction in a teenager associated with oral contraceptives, elevated lipoprotein a, and median arcuate ligament syndrome. Poster presentation at XXIV Congress of

the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29-July 4 2013, Amsterdam, The Netherlands.

Nakar C, Gupta S, Xavier F, Rampersad A, Hallett R, Natarajan K. A Case of Extensive Recalcitrant IVC Thrombosis in a Teenager with Behçet Disease. Poster presentation at XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29-July 4 2013, Amsterdam, The Netherlands.

Nakar C, Haddix C, Meschino N, Sagar J, Menshouse E, Fuentes I, Greist A, Shapiro A. Development and use of a surgical database to standardize care, assess efficacy and outcomes in bleeding disorder patients: report of 1184 procedures from a single center. Poster presentation at XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH) 57th Annual SSC Meeting, July 2011, Kyoto, Japan.

Angeli Rampersad, MD

Publications

Rampersad A, Hampton K, Duncan N, Roberson C, Slayten J, Davisson S, Aronowitz J, Shapiro A. Noninvasive buccal swab antigen sample and molecular testing provides extended antigen typing for patients with hemoglobinopathies. *Journal of Pediatrics* 2014;165(5):1003-7.

Nakar C, Gupta S, Xavier F, **Rampersad A**, Natarajan K. Abstract PO 301: A case of extensive recalcitrant IVC thrombosis in a teenager with Behçet disease. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):1132-33.

Rampersad AG, Shapiro AD, Rodriguez-Merchan EC, Maahs JA, Akins S, Jimenez-Yuste V. Radiosynovectomy: review of the literature and report from two haemophilia treatment centers. *Blood Coagul Fibrinolysis* 2013;24(5):465-70.

Xavier F, Maahs J, Hallett R, Nakar C, **Rampersad A**, Gupta S, Shapiro A. Abstract PO 173: Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):1086.

Presentations

Duncan N, Hampton K, **Rampersad A**, Roberson C, Kronenberger W, Shapiro A. Validation of an Antibiotic Prophylaxis Adherence Scale for Sickle Cell Disease. Poster presentation at the Sickle Cell Disease Association of America (SCDAA) 42nd Annual, October, 2014, Baltimore, MD. Presented by K Hampton.

Xavier F, Maahs J., Hallett R., Nakar C., **Rampersad A.**, Gupta S., Shapiro A. Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. Poster presentation at XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29- July 4 2013, Amsterdam, The Netherlands.

Nakar C., Gupta S., Xavier F., **Rampersad A.**, Hallett R., Natarajan K. A Case of Extensive Recalcitrant IVC Thrombosis in a Teenager with Behçet Disease. Poster presentation at XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH) 58th Annual SSC Meeting, June 29-July 4 2013, Amsterdam, The Netherlands.

Hampton K., Roberson C., **Rampersad A.**, Duncan N., Sealls W., Shapiro A. Indiana's Newborn Hemoglobinopathy Screening Program: Structure and Data from Initial 3 Years: The Sickle SAFE Program. Oral presentation at Sickle Cell Disease Association of America (SCDAA) 40th Annual Convention. September 2012, Baltimore, Maryland.

Amy Shapiro, MD

Publications

Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V. Integrated analysis of safety data from 12 clinical intervention studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. *Haemophilia* 2015:Epub ahead of print at <http://onlinelibrary.wiley.com/doi/10.1111/hae.12724/full>. Accessed June 5, 2014. DOI:10.1111/hae.12724.

Duncan NA, Roberson CP, **Shapiro AD**. Comment on: Khair K. Compliance, concordance and adherence: what are we talking about? *Haemophilia* Sept 2014;20(5):601–3. *Haemophilia* 2015;Online only.:DOI 10.1111/hae.12641.

Shapiro AD, Akins S, Cooper L. Long-term outcomes from orthopaedic surgery in haemophilia: are we measuring success and documenting and assessing complications? *Haemophilia* 2014;20(5):e367-e371.

Lock J, Raat H, Duncan N, **Shapiro A**, Beijlvelt M, Peters M, Tamminga RYJ, Leebeek FWG, Moll HA, Cnossen MH. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. *Haemophilia* 2014;20(5):616-23.

Rampersad A, Hampton K, Duncan N, Roberson C, Slayten J, Davisson S, Aronowitz J, **Shapiro A**. Noninvasive buccal swab antigen sample and molecular testing provides extended antigen typing for patients with hemoglobinopathies. *Journal of Pediatrics* 2014;165(5):1003-7.

Duncan N, Roberson C, Lail A, Donfield S, **Shapiro A**. A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals. *Haemophilia* 2014;20(4):519-26.

Heiman M, Gupta S, **Shapiro AD**. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. *Haemophilia* 2014;20(3):407-12.

Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, **Shapiro A**, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. *Blood* 2014;123(3):317-25.

Shapiro AD, Neufeld EJ, Blanchette V, Salaj P, Gut RZ, Cooper DL. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 mug kg⁻¹) rFVIIa doses across clinical trials and registries. *Haemophilia* 2014;20:e23-31.

Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT, **the Haemophilia Inhibitor Research Study Investigators**. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. *Haemophilia* 2014;20(2):230-7.

Plasminogen Activator Inhibitor Type 1 Deficiency. 2014. (Accessed July 30, 2014, at www.rarecoagulationdisorders.org.)

Plasminogen Deficiency. 2014. (Accessed July 30, 2014, at www.rarecoagulationdisorders.org.)

Astermark J, Donfield SM, Gomperts ED, Schwarz J, Menius ED, Pavlova A, Oldenburg J, Kessing B, Dimichele DM, **Shapiro AD**, Winkler CA, Berntorp E, Hemophilia Inhibitor Genetics Study Combined C. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. *Blood* 2013;121(8):1446-54.

DiPaola J, **Shapiro A**. Bleeding Disorders. American Society of Hematology Self-Assessment Program. 5th ed: American Society of Hematology; 2013.

Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissing C, Lusher JM, Ragni MV, **Shapiro AD**, Montgomery RR. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. *Blood* 2013;121(18):3742-4.

Hinckley JD, Abbott D, Burns TL, Heiman M, **Shapiro AD**, Wang K, De Paola J. Quantitative trait locus linkage analysis in a large Amish pedigree identifies novel candidate loci for erythrocyte traits. *Molecular Genetics and Genomic Medicine* 2013;1(3):131-41.

Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PHB, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Markris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, **Shapiro A**, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay for the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) J. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. *Human Molecular Genetics* 2013;22(9):1903-10.

Larsen DM, Haberichter SL, Gill JC, **Shapiro AD**, Flood VH. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. *Haemophilia* 2013;19(4):590-4.

Xavier F, Maahs J, Hallet R, Nakar C, Rampersad A, Gupta S, **Shapiro A**. Abstract PO 173: Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):1086.

Quon D, **Shapiro A**, Santagostino E, Valentino LA, Epstein J, Guzman-Becerra N, Schroth P, Wong W. Abstract PO 160: Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):1081.

Ragni M, Josephson N, Mahlangu J, Pasi J, Perry D, Powell J, **Shapiro A**, Krassova S, Greblikas F, Nugent K, Brennan A, Luk A, Pierce GF. Abstract PB 4.37-3: Treatment of bleeding episodes in subjects with haemophilia A with long-lasting recombinant Factor VIII Fc fusion protein (rFVIII-Fc) in the Phase 3 A-LONG study. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):928.

Lock J, Raat H, Duncan N, **Shapiro A**, Peters M, Tamminga Y, Leebeek F, Moll H, Cnossen M. Abstract PB 3.37-6: Adherence to hemophilia treatment in the Dutch pediatric population; reliability and validity of the VERITAS-Pro questionnaire. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):801.

Shapiro A, Khair K, Teitel J, Leony L, Matovinovic E, Schoenig-Diesing C, Spotts G. Abstract PB 1.37-3: Ongoing prospective rAHF-PFM immune tolerance induction registry (PAIR): success rates continue to support published literature. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):534.

Shapiro A, Romanov V, Silvati-Fidell L, Wong-WY, Schoenig-Diesing C. Abstract PB 1.36-4: Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in persons with hemophilia A (HemoA). *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):532.

Mahlangu J, Powell J, Josephson N, Klamroth R, Parra Lopez R, Morfini M, Oldenburg J, Pasi J, Perry D, Ragni M, **Shapiro A**, Dunkley S, Apte S, Krassova S, Greblikas F, Innes A, Nugent K, Brennan A, Luk A, Pierce GF. Abstract PA 4.07-2: Long-lasting recombinant factor VIII Fc fusion (rFVIII Fc) for perioperative management of subjects with haemophilia A in the phase 3 A-LONG study. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):459.

Li S, Diao L, Powell J, **Shapiro A**, Josephson N, Pasi J, Perry D, Ragni M, Kulkarni R, Valentino LA, Brennan A, Pierce GF, Nestorov I, Jiang H. Abstract PA 2.07-5: Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):358.

Neelakantan S, Li S, Josephson N, Pasi J, Perry D, **Shapiro A**, Ragni M, Kulkarni R, Fogarty P, Brennan A, Pierce G, Jiang H, Nestorov I. Abstract PA 2.06-3: Population pharmacokinetic analysis of long-lasting recombinant factor VIII Fc fusion protein (rFVIII Fc) in patients with severe haemophilia A. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):354.

Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, **Shapiro A**, Pasi J, Apte S, Krassova S, Jiang H, Li S, Cristiano LM, Neelakantan S, Greblikas F, Goyal J, Sommer J, Dumont J, Innes A, Nugent K, Brennan A, Luk A, Pierce GF. Abstract OC 37.2: A-LONG: results from Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor VIII Fc fusion protein (rFVIII Fc). *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):168.

Mannucci PM, Kempton C, Millar C, Romond E, **Shapiro A**, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong W-Y, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. *Blood* 2013;122(5):648-57.

Nakar C, Manco-Johnson MJ, Lail A, Donfield SM, Maahs J, Chong Y, Blades TA, **Shapiro AD**. Abstract: Prompt immune tolerance induction at inhibitor diagnosis regardless of titer may increase overall success in hemophilia A with inhibitors: experience of two US centers. *Blood* 2013;122(21):575.

Miller CH, Rice AS, Boylan B, **Shapiro AD**, Lentz SR, Wicklund BM, Kelly FM, Soucie JM, The Hemophilia Inhibitor Research Study Investigators. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. *Journal of Thrombosis & Haemostasis* 2013;11(7):1300-9.

Gupta S, **Shapiro A**. New recombinant factor concentrates. *International Monitor on Hemophilia* 2013;21:3-8.

Nakar C, **Shapiro A**. The optimal time to initiate immune tolerance induction. *The International Monitor* 2013;21 (1):21-2.

Rampersad AG, **Shapiro AD**, Rodriguez-Merchan EC, Maahs JA, Akins S, Jimenez-Yuste V. Radiosynovectomy: review of the literature and report from two haemophilia treatment centers. *Blood Coagul Fibrinolysis* 2013;24(5):465-70.

Schwarz J, Astermark J, Menius ED, Carrington M, Donfield SM, Gomperts E, Nelson G, Oldenburg J, Pavlova A, **Shapiro A**, Winkler CA, Berntorp from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort) E. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) combined cohort. *Haemophilia* 2013;19(1):113-8.

Shapiro AD. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. *Expert Opinion on Biological Therapy* 2013;13(9):1287-97.

Shapiro AD. Long-lasting recombinant factor VIII proteins for hemophilia A. *Hematology Am Soc Hematol Educ Program* 2013;2013:37-43.

Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, **Shapiro AD**, Abshire TC, Leissing C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. *Blood* 2012;119(9):2135-40.

Berntorp E, **Shapiro AD**, Waters J, Astermark J. The international factor IX treatment network survey. *Haemophilia* 2012;18(3):e60-2.

Berntorp E, **Shapiro AD**. Modern haemophilia care. *Lancet* 2012;379(9824):1447-56.

Chambost H, Rafowicz A, Guillaume Y, Liesner R, Nolan B, Shima M, **Shapiro A**, Ljung R. Abstract PO-TU-166: Perinatal practices in the context of hemophilia carrier: expert opinion from an international pediatric panel. *Haemophilia* 2012;18(Suppl 3):148-9.

Duncan N, **Shapiro A**, Ye X, Epstein J, Luo MP. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. *Haemophilia* 2012;18(5):760-5.

Escobar M, Maahs J, Hellman E, Donkin J, Forsyth A, Hroma N, Young G, Valentino LA, Tachdjian R, Cooper DL, **Shapiro AD**. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres. *Haemophilia* 2012;18(6):971-81.

Gomperts ED, Apte S, Chaudhuri U, John JM, Ramanan V, Liesner R, **Shapiro AD**, Mills BJ, Lee M. IB1001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B. *ASH Annual Meeting Abstracts* 2012;120(21):2225.

Greist A, **Shapiro A**, Kruse-Jarres R, St. Louis J, Smith H, Gomperts E. Abstract FP-MO-01.1-1: Efficacy and safety of B-domain deleted recombinant porcine factor FVIII (OB-1) in the treatment of acquired hemophilia A: interim results. *Haemophilia* 2012;18(Suppl 3):1.

Louis JS, Kruse-Jarres R, Greist A, **Shapiro AD**, Smith H, Drebes AB, Lozier JN, Gomperts ED. Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results. *ASH Annual Meeting Abstracts* 2012;120(21):2224.

Martinowitz U, **Shapiro A**, Quon DV, Escobar M, Kempton C, Collins PW, Chowdary P, Makris M, Mannucci PM, Morfini M, Valentino LA, Gomperts E, Lee M. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. *Haemophilia* 2012;18(6):881-7.

Nakar C, **Shapiro A**. Inhibitors, tolerance and alchemy. *The International Monitor* 2012;20(1):33-4.

Shapiro A, Cooper DL. U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors. *Haemophilia* 2012;18(3):400-5.

Shapiro A, Khair K, Ghandehari H, Song C, Leony-Lasso I, Schoenig-Diesing C, Spotts G. Abstract PO-WE-137: Prospective Advate Immune Tolerance Registry (PAIR) in hemophilia A patients with inhibitors: interim report. *Haemophilia* 2012;18(Suppl 3):95.

Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Ewart D, Li L, Hallen B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. *Blood* 2012;119(3):666-72.

Young G, **Shapiro AD**, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). *Haemophilia* 2012;18(3):392-9.

Aschman DJ, Abshire TC, **Shapiro AD**, Lusher JM, Forsberg AD, Kulkarni R. A community-based partnership to promote information infrastructure for bleeding disorders. *Am J Prev Med* 2011;41(6 Suppl 4):S332-7.

Gill JC, **Shapiro AD**, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. *Haemophilia* 2011;17(6):895-905.

Martinowitz U, **Shapiro AD**, Quon DV, Escobar MA, Kempton CL, Collins P, Chowdary P, Makris M, Mannucci PM, Morfini M, Valentino LA, Gomperts ED, Lee M. Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. *ASH Annual Meeting Abstracts* 2011;118(21):2267.

Nakar C, Haddix C, Meschino N, Sagar J, Menshouse E, Fuentes I, Greist A, **Shapiro A**. Abstract P-MO-543: Development and use of a surgical database to standardize care, assess efficacy and outcomes in bleeding disorders patients: report of 1184 procedures from a single center. *Journal of Thrombosis and Haemostasis* 2011;9(Suppl 2).

Shapiro A, Neufeld EJ, Blanchette V, Chambost V, Cooper D. Abstract P-TU-518: Safety of exposure to recombinant activated FVII (rFVIIa) doses in patients with congenital hemophilia with inhibitors (CHWI) to factors VIII or IX. *Journal of Thrombosis & Haemostasis* 2011;9(Suppl 2):471.

Shapiro A, Pipe S, Geraghty S, Pezalla E, Jorgenson J, Tadlock C, Wulff K, Kaminsky R, Kessler C. Hemophilia and managed care: partnering to achieve cost-effective care. *The American Journal of Pharmacy Benefits* 2011;3(5):248-55.

Shapiro AD, Hedner U. Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. *Therapeutic Advances in Drug Safety* 2011;2(5):213-25.

Shapiro AD, Neufeld EJ, Blanchette VS, Chambost H, Salaj P, Gut RZ, Cooper DL. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital hemophilia with inhibitors: overall dose exposure and intervals following >240 mcg/kg doses across trial, registry and diary studies. *ASH Annual Meeting Abstracts* 2011;118(21):3316.

Shapiro AD, Soucie JM, Peyvandi F, Aschman DJ, DiMichele DM. Knowledge and therapeutic gaps: a public health problem in the rare coagulation disorders population. *American Journal of Preventive Medicine* 2011;41(6 Suppl 4):S324-S31.

Sharathkumar A, Soucie JM, Trawinski B, Greist A, **Shapiro AD**. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). *Haemophilia* 2011;17(4):597-604.

Suiter TM, Mannucci PM, Kempton CL, Laffan M, Romond EH, **Shapiro AD**, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Horling FM, Reipert BM, Turecek PL, Varadi K, Chapman M, Engl W, Wong WY, Ewenstein BM, rhVWF Study Team. Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease. *ASH Annual Meeting Abstracts* 2011;118(21):2275.

Zhou ZY, Wu J, Baker J, Curtis R, Forsberg A, Huszti H, Koerper M, Lou M, Miller R, Parish K, Riske B, **Shapiro A**, Ullman M, Johnson K. Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data. *Haemophilia* 2011;17(5):729-36.

Presentations

Not listed.

Anand Tandra, MD

Publications

Lentz SR, **Tandra A**, Gut RZ, Cooper DL. A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project. *J Blood Med* 2014;5:1-3.

Other IHTC Staff

Publications

Duncan NA, Roberson CP, Shapiro AD. Comment on: Khair K. Compliance, concordance and adherence: what are we talking about? *Haemophilia* Sept 2014;20(5):601–3. *Haemophilia* 2015;Online only.:DOI 10.1111/hae.12641.

Shapiro AD, **Akins S**, Cooper L. Long-term outcomes from orthopaedic surgery in haemophilia: are we measuring success and documenting and assessing complications? *Haemophilia* 2014;20(5):e367-e371.

Rampersad A, **Hampton K, Duncan N, Roberson C**, Slayten J, Davisson S, Aronowitz J, Shapiro A. Noninvasive buccal swab antigen sample and molecular testing provides extended antigen typing for patients with hemoglobinopathies. *Journal of Pediatrics* 2014;165(5):1003-7.

Lock J, Raat H, **Duncan N**, Shapiro A, Beijlevelt M, Peters M, Tamminga RYJ, Leebeek FWG, Moll HA, Cnossen MH. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. *Haemophilia* 2014;20(5):616-23.

Duncan N, Roberson C, Lail A, Donfield S, Shapiro A. A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals. *Haemophilia* 2014;20(4):519-26.

Heiman M, Gupta S, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. *Haemophilia* 2014;20(30):407-12.

Hinckley JD, Abbott D, Burns TL, **Heiman M**, Shapiro AD, Wang K, De Paola J. Quantitative trait locus linkage analysis in a large Amish pedigree identifies novel candidate loci for erythrocyte traits. *Molecular Genetics and Genomic Medicine* 2013;1(3):131-41.

Lock J, Raat H, **Duncan N**, Shapiro A, Peters M, Tamminga Y, Leebeek F, Moll H, Cnossen M. Abstract PB 3.37-6: Adherence to hemophilia treatment in the Dutch pediatric population; reliability and validity of the VERITAS-Pro questionnaire. *Journal of Thrombosis & Haemostasis* 2013;11(Suppl 2):801.

Nakar C, Manco-Johnson MJ, Lail A, Donfield SM, Maahs J, **Chong Y**, Blades TA, Shapiro AD. Abstract: Prompt immune tolerance induction at inhibitor diagnosis regardless of titer may increase overall success in hemophilia A with inhibitors: experience of two US centers. 2013;122(21):575.

Rampersad AG, Shapiro AD, Rodriguez-Merchan EC, Maahs JA, **Akins S**, Jimenez-Yuste V. Radiosynovectomy: review of the literature and report from two haemophilia treatment centers. *Blood Coagul Fibrinolysis* 2013;24(5):465-70.

Duncan N, Shapiro A, Ye X, Epstein J, Luo MP. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. *Haemophilia* 2012;18(5):760-5.

Nakar C, **Haddix C, Meschino N, Sagar J, Menshouse E**, I, Greist A, Shapiro A. Abstract P-MO-543: Development and use of a surgical database to standardize care, assess efficacy and outcomes in bleeding disorders patients: report of 1184 procedures from a single center. *Journal of Thrombosis and Haemostasis* 2011;9(Suppl 2).

Sharathkumar A, Soucie JM, **Trawinski B**, Greist A, Shapiro AD. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). *Haemophilia* 2011;17(4):597-604.

Presentations

Hampton K. Expansion of the Sickle SAFE Program: Birth to 5 Years. Oral presentation at the Sickle Cell Disease Association of America (SCDAA) 42nd Annual, October 2014, Baltimore, MD.

Duncan N, Hampton K, Rampersad A, **Roberson C,** Kronenberger W, Shapiro A. Validation of an Antibiotic Prophylaxis Adherence Scale for Sickle Cell Disease. Poster presentation at the Sickle Cell Disease Association of America (SCDAA) 42nd Annual, October 2014, Baltimore, MD. Presented by K Hampton.

Hampton K. Proposed Framework for Long-Term Follow-up for Infants and Children With Hemoglobinopathies. Oral presentation at the Sickle Cell Disease Association of America 42nd Annual Convention, October 2014, Baltimore, MD.

Duncan N, Krishnan S, Kronenberger W, Shapiro A. Adherence to Prophylactic Treatment in Hemophilia as Measured Using the VERITAS-Pro and Factor Doses Administered and Annual Bleed Rate (ABR). Poster presentation at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, June 2014, Montreal, QC, Canada. Presented by S. Krishnan.

Duncan N, Krishnan S, Kronenberger W, Shapiro A. Adherence to Prophylactic Treatment in Hemophilia as Measured Using the VERITAS-Pro and Factor Doses Administered and Annual Bleed Rate (ABR). Poster presentation at World Federation of Hemophilia (WFH) World Congress, May 2014, Melbourne, VIC, Australia.

Bloom E, Hampton K. Expansion of the Sickle SAFE Program from Birth to 5. Oral presentation at Region 4 Genetic Collaborative Regional Meeting, April 2014, Lansing, MI.

Bloom E. School Accommodations for Sickle Cell Disease. Oral presentation at Regional Conferences for School Nurses hosted by Indiana State Department of Health, Various Indiana locations, April 2014.

Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, **Chong Y,** Blades T, Shapiro A. Prompt Immune Tolerance Induction at Inhibitor Diagnosis Regardless of Titer May Increase Overall Success in Hemophilia A with Inhibitors: Experience of Two US Centers. Oral presentation at American Society of Hematology (ASH) 56th Annual Meeting. December 2013, New Orleans, LA.

Duncan N. B Does Not Equal A: Update on Hemophilia B. Oral presentation at National Hemophilia Foundation (NHF) Annual Meeting. October 2013, Anaheim, CA.

Hampton K. Newborn Screening Follow-up in Indiana for Hemoglobinopathies. Oral presentation at 140th American Public Health Association (APHA) Annual Meeting. October 2013, San Francisco, CA.

Duncan N. Adherence Scale in Hemophilia. Oral presentation at International Society on Thrombosis and Haemostasis (ISTH). June 2013, Amsterdam, Holland, The Netherlands.

Hampton K. What All Early Care and Educational Professionals Need to Know About Sickle Cell Disease. Oral presentation at 2013 Indiana Early Childhood Conference, April 2013.

Hampton K. Newborn Screening in Indiana-The Sickle-SAFE Program. Oral presentation at Sickle Cell Association of Illinois Annual Sickle Cell Conference, February 2013, Oaklawn, IL.

Asirwa FC, Greist A, **Roberson C.** AMPATH Hematology: Collaboration between Indiana Hemophilia & Thrombosis Center (IHTC), Indiana University and Moi University, Eldoret (Kenya). Poster presentation at the 2nd Global Sickle Cell Disease Network, March 2012, Atlanta, GA.

Hampton K, Roberson CP, Rampersad, Shapiro A, Slayten J, Aronowitz J. Use of Non-invasive Buccal Swab Samples for RBC Antigen Testing in Newborns with Hemoglobinopathies. Oral presentation at Sickle Cell Disease Association of America (SCDAA) 40th Annual Convention. September 2012, Baltimore, MD.

Hampton K. Newborn Screening Follow-up in Indiana for Hemoglobinopathies. Oral presentation at Region 4 Genetics Collaborative. September 2012, Lansing, MI.

Hampton K., Roberson C., Rampersad A., **Duncan N.,** Sealls W., Shapiro A. Indiana's Newborn Hemoglobinopathy Screening Program: Structure and Data from Initial 3 Years: The Sickle SAFE Program. Oral presentation at Sickle Cell Disease Association of America (SCDAA) 40th Annual Convention. September 2012, Baltimore, Maryland.

Duncan N. Project Update: VERITAS-Pro and PRN *and* Adherence Survey Results. Oral presentations at International Network of Pediatric Hematologists (INPH) Annual Meeting. July 2012, Paris, France.

Duncan N. Evaluation of Adherence to Hemophilia Treatment as Measures Using VERITAS Scales. Oral presentation at National Conference on Blood Disorders in Public Health, March 2012, Atlanta, GA.

Hampton K. Indiana Sickle-SAFE NBS Program. Oral presentation at South Bend Sickle Cell Conference. October 2011, South Bend, IN.

Nakar C, **Haddix C, Meschino N, Sagar J, Menshouse E,** Fuentes I, Greist A, Shapiro A. Development and use of a surgical database to standardize care, assess efficacy and outcomes in bleeding disorder patients: report of 1184 procedures from a single center. Poster presentation at XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH) 57th Annual SSC Meeting, July 2011, Kyoto, Japan.